We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0RHR market cap is 314.73M. The company's latest EPS is CHF -0.3734 and P/E is -24.24.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | |
| Total Revenue | 2.56M | 4.04M | 13.82M | 17.99M | 33.56M |
| Operating Income | -11.39M | -11.68M | -8.77M | -13.45M | -13.19M |
| Net Income | -11.25M | -11.52M | -7.54M | -14.6M | -13.73M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | |
| Total Assets | 87.85M | 94.36M | 91.34M | 82.95M | 71.46M |
| Total Liabilities | 10M | 9.76M | 14.36M | 14.09M | 14.75M |
| Total Equity | 77.86M | 84.6M | 76.98M | 68.86M | 56.71M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | CHF (CHF) | |
| Operating | -10.85M | -9.24M | -5.45M | -7.35M | -8.84M |
| Investing | -118k | -220k | -374k | -400k | -326k |
| Financing | 13.13M | 17.08M | 6.08M | 3.22M | -171k |
| Market Cap | 314.73M |
| Price to Earnings Ratio | -24.24 |
| Price to Sales Ratio | 9.91 |
| Price to Cash Ratio | 23.42 |
| Price to Book Ratio | 5.87 |
| Dividend Yield | - |
| Shares Outstanding | 36.77M |
| Average Volume (1 week) | 45.05k |
| Average Volume (1 Month) | 17.9k |
| 52 Week Change | 0.00% |
| 52 Week High | 8.56 |
| 52 Week Low | 8.56 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Kuros Biosciences Ag |
| Address |
wagistrasse 25 zurich 8952 |
| Website | https://www.kurosbio.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
